etrasimod
Phase 3- Indications
- Ulcerative colitis, Crohn's disease, Atopic dermatitis, Eosinophilic esophagitis, Alopecia areata
Company intelligence / Profile preview
Arena Pharmaceuticals has multiple clinical-stage programs, with etrasimod being the most advanced candidate in Phase 3 trials for ulcerative colitis and other inflammatory conditions. The company was acquired by Pfizer in March 2022 for $6.7 billion.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Arena Pharmaceuticals, Inc..